For most people, these effects were temporary, and their bodies adjusted over time
Propensity matching was used to assess whether prescribed semaglutide was associated with NAION in patients with type 2 diabetes (T2D) or overweight/obesity, in each case accounting for covarying factors (sex, age, systemic hypertension, T2D, obstructive sleep apnoea, obesity, hyperlipidemia, and coronary artery disease) and contraindications for use of semaglutide
GLP-1s change your brain chemistry
The study, which analyses data for patients receiving weight loss drugs across 11 randomised trials, suggests that while the amount of weight regain varies depending on the specific drug, there is a broad trend in associated weight regain after the course of medication concluded